Bristol Myers Squibb to present late-breaking iza-bren, pumitamig and Opdivo plus Yervoy data across solid tumours at ESMO 2026
Posted on October 20, 2026
Bristol Myers Squibb will present new data from its oncology portfolio and pipeline across a broad range of solid tumours at the European Society for Medical Oncology Congress 2026, held from 23 to 27 October in Madrid, Spain. The company will give 12 oral presentations and nearly 60 disclosures in total.
The headline presentations include late-breaking global Phase 2 data for pumitamig, an investigational PD-L1 x VEGF-A bispecific immunomodulator being developed jointly with BioNTech. There are also two late-breaking Phase 3 studies of izalontamab brengitecan (iza-bren), a potential first in class EGFR x HER3 bispecific antibody drug conjugate sponsored by Sichuan Biokin Pharmaceutical Co., Ltd., the parent company of SystImmune. A third highlight is long term survival data for Opdivo® plus Yervoy® from a late-breaking Phase 3 oral presentation.
Cristian Massacesi, MD, executive vice president, chief medical officer and head of development at Bristol Myers Squibb, said the company is advancing a new generation of oncology medicines aimed at some of the most persistent challenges facing people with cancer. He said ESMO 2026 will showcase data from both emerging and established treatment approaches, from new Phase 3 iza-bren results and new pumitamig findings to long term survival data for Opdivo plus Yervoy. He added that the results reflect the breadth of the pipeline and a focus on turning differentiated science into meaningful, durable outcomes for patients.
Bristol Myers Squibb presentations at ESMO 2026 (Madrid local time)
Thoracic cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| A Global Phase 2, Open-label Trial of Pumitamig (PD-L1 × VEGF-A bsAb) + Docetaxel Post-chemoimmunotherapy in mNSCLC: First Data from ROSETTA Lung-107 | Cho | Rapid oral #LBA76, Rapid Oral 2: NSCLC, Metastatic, Sunday 25 October, 8:30 to 10:00 AM |
| PANKU-Lung01: Randomized Phase 3 Study of Izalontamab Brengitecan (iza-bren) in EGFR-Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progression on a Third Generation EGFR TKI | Zhang | Proffered paper #LBA71, Proffered Paper 2: NSCLC, Metastatic, Monday 26 October, 8:30 to 10:00 AM |
| Phase 2 Study of Izalontamab Brengitecan (iza-bren) Plus Osimertinib in Patients with EGFR Mutant Locally Advanced or Metastatic NSCLC | Zhou | Poster #2575P, Poster Display Session, Monday 26 October, 12:00 to 12:45 PM |
Breast and thoracic cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| Efficacy of Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Patients with SCLC and TNBC with Brain Metastases: Subgroup Analyses of Two Phase 2 Trials | Pavlakis | Rapid oral #1951RO, Rapid Oral: Investigational Immunotherapy, Saturday 24 October, 8:30 to 10:00 AM |
Breast cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| PANKU-Breast01: Randomized Phase 3 Study of Izalontamab Brengitecan (iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic (LA/M) Hormone Receptor-Positive/HER2-negative (HR+/HER2-) Breast Cancer (BC) | Lan | Proffered paper #LBA50, Proffered Paper 1: Breast Cancer, Early and Advanced Stage, Friday 23 October, 1:30 to 3:00 PM |
Head and neck cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| Phase 2 Study of Izalontamab Brengitecan (iza-bren) Plus Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Ji | Rapid oral #1542RO, Rapid Oral: Head and Neck Cancer, Sunday 25 October, 2:45 to 4:15 PM |
Gastrointestinal cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| Prevalence, Prognosis, and Impact on Tumor Microenvironment of Homozygous MTAP Deletion in Advanced Solid Tumors | Rodón | Poster #4445P, Poster Display Session, Friday 23 October, 3:15 to 4:00 PM |
| Final Overall Survival Results from CheckMate 8HW: Nivolumab plus Ipilimumab vs Nivolumab or Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer | Lonardi | Rapid oral #LBA32, Rapid Oral: Gastrointestinal Tumours, Lower Digestive, Saturday 24 October, 2:45 to 4:15 PM |
Genitourinary cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| Results From a Phase 3 Trial of Neoadjuvant Chemotherapy Alone vs in Combination with Nivolumab Followed by Postsurgical Adjuvant Nivolumab in Patients with Muscle-Invasive Bladder Cancer | Necchi | Proffered paper #4736O, Proffered Paper 1: Genitourinary Tumour, Renal and Urothelial, Friday 23 October, 1:30 to 3:00 PM |
Pan tumour cancer
| Abstract title | Lead author | Presentation details |
|---|---|---|
| First Results from a Phase 2 Trial of Second-Line Pumitamig (PD-L1 × VEGF-A bsAb) Plus Chemotherapy in Unresectable Neuroendocrine Neoplasms | Xu | Proffered paper #2393O, Proffered Paper: NETs and Endocrine Tumours, Monday 26 October, 10:15 to 11:45 AM |
| When Overall Survival Is Not Enough: The Emerging Need for Context-Sensitive Endpoint Frameworks in Oncology | Cardone | Proffered paper #3315O, Proffered Paper: Policy, Sunday 25 October, 10:15 to 11:45 AM |
Related Topics and Keywords
Biopharma, biopharma news, bladder cancer, BMS, breast cancer, Bristol-Myers Squibb, colorectal cancer, ESMO 2026, Iza-bren, Izalontamab Brengitecan, lung cancer, Oncology, Opdivo, Pumitamig, Yervoy
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
